Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5
- Registration Number
- NCT00807170
- Locations
- 🇳🇱
Research site, Maastricht, Netherlands
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 117
- Registration Number
- NCT00777179
- Locations
- 🇰🇷
Research Site, Seoul, Republic of Korea, Korea, Republic of
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 74
- Registration Number
- NCT00757692
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 124
- Registration Number
- NCT00753714
- Locations
- 🇮🇹
Research Site, Roma, Italy
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract CancerGallbladder CancerCancer Of The Extrahepatic Bile DuctAmpullary Carcinoma
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 174
- Registration Number
- NCT00753675
- Locations
- 🇮🇹
Research Site, Torino, Italy
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Lung CancerLymphomaLymphoproliferative DisorderSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-03-16
- Target Recruit Count
- 18
- Registration Number
- NCT00734890
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionEsophageal Cancer
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00732745
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 34
- Registration Number
- NCT00720083
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
- Conditions
- Lung CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 162
- Registration Number
- NCT00687297
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Ocean Medical Center, Brick, New Jersey, United States
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 17
- Registration Number
- NCT00686036
- Locations
- 🇨🇦
Research Site, Granby, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.